This Viewpoint describes reforms to the ways the National Health Service (NHS) appraises cost-effectiveness and coverage of cancer drugs in England and Wales, the role of the National Institute for Health and Care Excellence (NICE) in the process, and changes in drug approval rates and access to new drugs as a result.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2BIhWGd
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction che...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jCvX3K via IFTTT
-
Injuries (unintentional and intentional) are the main cause of death and disability worldwide, including Jordan. The main purpose of this ho...
-
Coenzyme Q (CoQ) is a key component of the mitochondrial respiratory chain, but it also has several other functions in the cellular metaboli...
-
Related Articles Audiologic and radiologic findings in cochlear hypoplasia. Auris Nasus Larynx. 2017 Jan 10;: Authors: Cinar BC, Bat...
-
Vol.25 No.2 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1P7bHxT via IFTTT
-
Abstract Although patients with rheumatoid arthritis (RA) are prone to osteoporosis, tight control of disease activity might have a positi...
-
Omalizumab is a treatment for asthma that has a success rate of approximately 40% to 50%.1 Recent mechanistic studies have suggested that ba...
-
Understanding Head And Neck Cancers - The Southeast Sun ... The Southeast Sun (NAPSI)—According to the Centers for Disease Control an...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου